Atlas Trials

Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas

Clinical trial NCT03732495 · UNKNOWN

Trial details

NCT number
NCT03732495
Sponsor
Centre Leon Berard
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Thyroid Cancer Metastatic
Start date
2019-07-26
Primary completion
2022-12-15
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.